Functional medicinal particles, their manufacturing method, and orally disintegrating tablets

By incorporating a 4% mannitol outermost layer in the coating of spherical core particles, the cracking issue in enteric-coated orally disintegrating tablets is resolved, enhancing mechanical stability and disintegration performance.

JP7583542B2Active Publication Date: 2024-11-14TOWA PHARMACEUTICAL CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020122357
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-07-16
Publication Date
2024-11-14
Estimated Expiration
2040-07-16

AI Technical Summary

Technical Problem

Orally disintegrating tablets with enteric coatings are prone to cracking due to the hardness and difficulty in plastic deformation of functional medicinal particles, leading to void formation and mechanical instability during compression.

Method used

The use of spherical core particles coated with a release control layer and an outermost layer containing at least 4% mannitol by mass, which absorbs stress and prevents cracking during tablet formation.

Benefits of technology

Suppresses the occurrence of cracks in orally disintegrating tablets, ensuring ease of formulation design and improved disintegration properties while maintaining mechanical integrity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583542000001
    Figure 0007583542000001
  • Figure 0007583542000002
    Figure 0007583542000002
  • Figure 0007583542000003
    Figure 0007583542000003
Patent Text Reader

Abstract

To provide pharmaceutically effective particles in which occurrence of a crack in a tablet itself can be suppressed even if tableting is performed in order to prepare an orally disintegrating tablet.SOLUTION: Pharmaceutically effective particles that are formed of: a spherical core part including a pharmaceutically effective component; and a coating part which coats the spherical core part, and includes a release control layer and an outermost layer including mannitol, in which a ratio of mannitol included in the outermost layer is adjusted to 4 mass% or more in the pharmaceutically effective particles. As the coating part, a first shielding layer, a second shielding layer, a first enteric layer, a middle layer, a second enteric layer and the outermost layer may be sequentially laminated on the spherical core part. The pharmaceutically effective particles and rapidly disintegrating particles may be combined to prepare an orally disintegrating tablet. The rapidly disintegrating particles include sugar alcohol and carmellose, and a ratio of crystalline cellulose may be less than 1 mass% in the particles.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to functional medicinal particles for preparing orally disintegrating tablets, a method for producing the same, and orally disintegrating tablets comprising the particles. [Background technology]

[0002] Orally disintegrating tablets (OD tablets) are tablets designed to disintegrate in a short time by saliva in the oral cavity, so that they can be taken by patients, elderly people, and children who have difficulty swallowing solid preparations designed to release medicinal ingredients in the digestive tract. These OD tablets are usually prepared by a method in which medicinal ingredients-containing particles coated with a functional coating layer are mixed with other ingredients including excipients and compressed into tablets. However, since oral disintegration is required for OD tablets, it is difficult to maintain the mechanical properties of the tablet, and tableting problems are likely to occur. In particular, when the functional coating layer is an enteric layer (enteric coating layer), the number of layers increases, making the tablet hard and prone to tableting problems. The following solid preparations are known as solid preparations that suppress tableting problems.

[0003] Japanese Patent Laid-Open Publication No. 3-240723 (Patent Document 1) discloses a tablet containing granules for tableting in which fine granules containing a drug are fluidized and coated with an aqueous lactose suspension to suppress tableting problems such as capping, in which the surface of the tablet on the upper punch side peels off, and hitching and squeaking, in which raw drug powder adheres to the punch or die during tableting. This document gives an example of mannitol as a drug that causes tableting problems.

[0004] In Japanese Patent No. 5366558 (Patent Document 2), an orally disintegrating solid preparation containing fine granules A in which the outermost layer of the fine granules is coated with a coating layer containing hydroxypropylmethylcellulose and low-substituted hydroxypropylcellulose, and the release of the medicament active ingredient is controlled, is disclosed as a preparation in which a part of the coating film of the fine granules contained in the preparation is destroyed during tableting, and the coating film is prevented from decreasing the bitterness masking effect and acid resistance. This document also discloses an orally disintegrating solid preparation in which the fine granules A and fine granules B, which have a release rate of the medicament active ingredient different from that of the fine granules A, are combined, and it is described that the fine granules B may be overcoated with mannitol in order to improve the strength of the orally disintegrating tablet. In the examples, as the fine granules B, 260 mg of enteric fine granules containing 7.63 g of methacrylic acid copolymer LD are overcoated with 10 mg of mannitol.

[0005] Japanese Patent No. 6440313 (Patent Document 3) discloses a layered tablet in which a layer containing an active ingredient is coated with a layer containing an antacid, one or more disintegrants selected from lactose, mannitol, and sorbitol, and one or more disintegrants selected from low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, and croscarmellose sodium, as a layered tablet in which tabletting problems such as binding, in which scratches are caused on the side of the tablet, and picking, in which at least one convex part of the tablet peels off into a cap, are suppressed. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 3-240723 [Patent Document 2] Patent No. 5366558 [Patent Document 3] Patent No. 6440313 Summary of the Invention [Problem to be solved by the invention]

[0007] The present inventors have noticed that when preparing an orally disintegrating tablet by mixing functional medicinal particles coated with an enteric layer and fast-disintegrating particles not containing a medicinal ingredient and tableting the mixture, cracks occur on the side of the obtained orally disintegrating tablet itself along a direction approximately perpendicular to the thickness direction. The cause of such cracks is not clearly known, but it can be assumed that the functional medicinal particles coated with an enteric layer are hard and difficult to plastically deform, so that voids are easily formed around the functional medicinal particles, which causes cracks. However, none of Patent Documents 1 to 3 describes the inhibition of cracks in the tablet itself. In addition, Patent Documents 1 and 3 do not describe orally disintegrating tablets.

[0008] Therefore, an object of the present invention is to provide functional medicinal particles that can suppress the occurrence of cracks in the tablet itself even when compressed to prepare an orally disintegrating tablet, a production method thereof, and an orally disintegrating tablet. [Means for solving the problem]

[0009] As a result of intensive research into achieving the above-mentioned object, the present inventors have found that in medicinal particles (functional medicinal particles) which are formed of a spherical core containing an active ingredient and a coating which covers the spherical core and which comprises a release-controlling layer and an outermost layer containing mannitol, by adjusting the proportion of mannitol contained in the outermost layer to 4 mass% or more in the medicinal particles, the occurrence of cracks in the tablet itself can be suppressed even when the tablet is compressed to prepare an orally disintegrating tablet, and have completed the present invention.

[0010] That is, the medicinal particle (functional medicinal particle) of the present invention is a medicinal particle formed of a spherical core containing a medicinal ingredient and a coating part that covers the spherical core and includes a release control layer and an outermost layer containing mannitol, and the proportion of mannitol contained in the outermost layer is 4% by mass or more in the medicinal particle. The release control layer may be an enteric layer. The coating part may further include a shielding layer interposed between the enteric layer and the spherical core. The coating part may include a first shielding layer, a second shielding layer, a first enteric layer, an intermediate layer, a second enteric layer, and an outermost layer laminated in this order on the spherical core. The particle hardness of the medicinal particle may be 400 gf or more. The outermost layer may not contain a disintegrant. The medicinal ingredient may be esomeprazole or a salt and / or solvate thereof. The medicinal particle may have a median particle size of 460 to 550 μm.

[0011] The present invention also includes a method for producing the medicinal particles, in which the medicinal particles are obtained by covering a spherical core with a coating portion.

[0012] The present invention also includes an orally disintegrating tablet containing the medicinal particles. The orally disintegrating tablet may further contain rapidly disintegrating particles. The rapidly disintegrating particles may contain sugar alcohol and carmellose, and the proportion of crystalline cellulose in the particles may be less than 1% by mass. The rapidly disintegrating particles may not contain a medicinal ingredient.

[0013] The present invention also includes a method for suppressing the occurrence of cracks during tableting to prepare an orally disintegrating tablet containing medicinal particles, the method comprising: (a) coating the spherical core with a coating portion that includes a release-controlling layer and an outermost layer that includes mannitol; and (b) adjusting the proportion of mannitol in the outermost layer to 4 mass% or more in the medicinal particles. Effect of the Invention

[0014] In the present invention, in a medicinal particle formed of a spherical core containing a medicinal ingredient and a coating portion covering the spherical core and including a release control layer and an outermost layer containing mannitol, the proportion of mannitol contained in the outermost layer is adjusted to 4% by mass or more in the medicinal particle, so that even when compressed to prepare an orally disintegrating tablet, the occurrence of cracks in the tablet itself can be suppressed. In particular, when an orally disintegrating tablet is prepared by combining with a specific fast-disintegrating particle, the occurrence of cracks can be suppressed to a high degree while ensuring formulation designability, and the oral disintegration property and the feeling of taking the tablet can also be improved. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] [Globular nucleus] The medicinal particles (functional medicinal particles) of the present invention contain a spherical core in the center, and this spherical core contains a medicinal ingredient (effective ingredient or active ingredient).

[0016] As the medicinal ingredient, any of conventional or novel medicinal ingredients can be used, including, for example, tonics, antipyretics, analgesics, anti-inflammatory drugs, psychotropics, anxiolytics, antidepressants, hypnotics, sedatives, antispasmodics, gastrointestinal drugs, antacids, antitussives and expectorants, dental and oral medicines, antihistamines, cardiac stimulants, antiarrhythmic drugs, diuretics, antihypertensives, vasoconstrictors, coronary vasodilators, peripheral vasodilators, choleretics, antibiotics, chemotherapy drugs, diabetes drugs, osteoporosis drugs, skeletal muscle relaxants, etc. Among these, medicinal ingredients that are easily decomposed by gastric juice (gastric acid) and require an enteric layer (e.g., antiulcer drugs such as esomeprazole or its salts and / or solvates, etc.) are preferred.

[0017] This spherical core portion is not particularly limited as long as it contains such an effective ingredient and is approximately spherical, but is usually a spherical core portion formed from the effective ingredient alone, or a spherical core portion formed from a complex of the effective ingredient and other ingredients such as excipients.

[0018] The proportion of the medicinal ingredient may be 10% by mass or more in the spherical core depending on the type of medicinal ingredient, for example, 20% by mass or more, preferably 30% by mass or more, more preferably 40% by mass or more, and most preferably 50% by mass or more. When the spherical core is formed of the above-mentioned complex, the proportion of the medicinal ingredient may be 10 to 90% by mass in the spherical core agent, for example, 20 to 80% by mass, preferably 30 to 70% by mass, and more preferably 40 to 60% by mass. If the proportion of the medicinal ingredient is too small, the particle size of the medicinal particles will become large, which may reduce the ease of formulation design.

[0019] An example of a spherical core formed solely from a medicinal ingredient is a spherical crystal of the medicinal ingredient.

[0020] An example of a spherical core formed from a complex is a complex in which the surface of a spherical excipient is coated with a composition containing a medicinal component.

[0021] As the spherical excipient, conventional spherical core particles for pharmaceutical preparations can be used. Examples of excipients constituting the spherical excipient include sugars such as lactose, glucose, fructose, maltose, sucrose, sucrose, white sugar, and powdered reduced maltose syrup; sugar alcohols such as sorbitol, mannitol, reduced maltose syrup (maltitol), reduced starch syrup, xylitol, reduced palatinose, and 4-carbon sugars (e.g., erythritol) obtained by fermenting glucose; celluloses such as microcrystalline cellulose, crystalline cellulose, and powdered cellulose; and alkyl celluloses such as methyl cellulose (MC) and ethyl cellulose (EC). These excipients can be used alone or in combination of two or more. Among these, sugars such as lactose and white sugar, sugar alcohols such as mannitol, and celluloses such as crystalline cellulose are preferred, and a combination of a sugar such as lactose and a cellulose such as crystalline cellulose is particularly preferred.

[0022] The proportion of the spherical excipient is, for example, 1 to 50 parts by mass, preferably 5 to 40 parts by mass, more preferably 10 to 30 parts by mass, and most preferably 15 to 25 parts by mass, relative to 100 parts by mass of the active ingredient.

[0023] The composition coating the spherical excipient may further comprise a binder in addition to the active ingredient.

[0024] Examples of binders include synthetic polymers such as polyvinylpyrrolidones (povidone, vinyl acetate-vinylpyrrolidone copolymer, etc.), polyvinyl alcohol, carboxyvinyl polymers, polyacrylic acid polymers (sodium polyacrylate, acrylic acid copolymer, etc.), polylactic acid, polyethylene glycol, and polyvinyl acetate; cellulose ethers such as carboxymethylcellulose (carmellose or CMC), carboxymethylethylcellulose (CMEC), hydroxyethylcellulose, hydroxypropylcellulose (HPC), and hydroxypropylmethylcellulose (hypromellose or HPMC); and cellulose esters such as cellulose acetate.

[0025] These binders can be used alone or in combination of two or more. Among these, hydroxy C such as hypromellose is preferred. 2-4 Alkyl C 1-2 Alkylcelluloses are preferred.

[0026] The ratio of the binder is, for example, 5 to 100 parts by mass, preferably 10 to 80 parts by mass, more preferably 30 to 70 parts by mass, and most preferably 40 to 60 parts by mass, relative to 100 parts by mass of the medicinal ingredient. If the ratio of the binder is too low, it may be difficult to attach the medicinal ingredient to the surfaces of the spherical parts, and conversely, if it is too high, the particle size of the medicinal particles may become large.

[0027] The composition may further contain an excipient in addition to the medicinal ingredient. Examples of the excipient include the excipients exemplified in the section on spherical excipients. The excipients may be used alone or in combination of two or more. Among the excipients, sugar alcohols such as mannitol are preferred, and D-mannitol is particularly preferred.

[0028] The ratio of the excipient is, for example, 1 to 30 parts by mass, preferably 2 to 20 parts by mass, more preferably 3 to 15 parts by mass, and most preferably 5 to 10 parts by mass, relative to 100 parts by mass of the medicinal ingredient. If the ratio of the excipient is too low, there is a risk that the medicinal particles will be less resistant to side cracking, and conversely, if the ratio is too high, there is a risk that the particle size of the medicinal particles will become large.

[0029] The composition may further contain conventional additives in addition to the active ingredient.

[0030] Examples of commonly used additives include disintegrants, lubricants, plasticizers, surfactants, pH adjusters, colorants, sweeteners or flavoring agents (aspartame, acesulfame potassium, sucralose, ascorbic acid, stevia, crude licorice extract, simple syrup, etc.), flavoring agents or refreshing agents (yogurt micron, peppermint micron, menthol, ginger oil, etc.), antioxidants [dibutylhydroxytoluene (BHT), propyl gallate, butylhydroxyanisole (BHA), tocopherol, citric acid, etc.], preservatives or preservatives (sodium benzoate, paraoxybenzoic acid esters, etc.), wetting agents, antistatic agents, disintegration aids, etc.

[0031] Examples of disintegrants include cross-linked polyvinylpyrrolidones such as crospovidone (cross-linked polyvinylpyrrolidone) and crospovidone copolymer; cellulose ethers such as carmellose sodium, carmellose calcium, croscarmellose sodium, and low-substituted hydroxypropylcellulose (L-HPC); polysaccharides such as agar, carrageenan, gum arabic, alginic acid, sodium alginate, propylene glycol alginate, guar gum, locust bean gum, gum arabic, tragacanth gum, pullulan, xanthan gum, hyaluronic acid, pectin, and sodium chondroitin sulfate; proteins such as gelatin, casein, and soybean protein; silicic acids such as talc, light anhydrous silicic acid, calcium silicate, magnesium silicate, synthetic aluminum silicate, and magnesium aluminometasilicate; and minerals such as bentonite, synthetic hydrotalcite, and kaolin.

[0032] Examples of lubricants include fatty acids or metal salts thereof (fatty acids or salts thereof such as stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, and sodium coconut oil fatty acid; silicon oxides such as hydrous silicon dioxide (hydrous silicic anhydride) and silicon dioxide; polyorganosiloxanes such as dimethylpolysiloxane; fats and oils such as hardened oils and cocoa butter; and waxes such as beeswax, white beeswax, carnauba wax, lanolin, paraffin, and petrolatum.

[0033] Examples of the plasticizer include hydrophilic plasticizers such as ethylene glycol, propylene glycol, and glycerin; and fat-soluble plasticizers such as triacetin, triethyl citrate, diethyl phthalate, dioctyl adipate, lauric acid, stearyl alcohol, and cetanol.

[0034] Examples of surfactants include macrogols such as polyethylene glycol having a weight average molecular weight of 300 to 6000; polyoxyethylene polyoxypropylene glycols such as Pluronic (registered trademark) and poloxamer; polyoxyethylene sorbitan fatty acid esters (polysorbates) such as polysorbate 80; polyoxyethylene hydrogenated oils such as polyoxyethylene hydrogenated castor oil; glycerin fatty acid esters such as glycerin monostearate; sorbitan fatty acid esters such as sorbitan monostearate and sorbitan monolaurate; sucrose fatty acid esters such as sucrose laurate; and fatty acid metal salts such as sodium lauryl sulfate.

[0035] Examples of pH adjusters include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, etc.; organic acids such as acetic acid, citric acid, etc.; inorganic bases such as sodium hydroxide, sodium hydrogen carbonate, etc.; and organic bases such as amines, etc.

[0036] Examples of coloring agents include yellow ferric oxide, ferric oxide, Food Blue No. 1, Food Blue No. 2, Food Yellow No. 4, Food Yellow No. 5, Food Green No. 3, Food Red No. 2, Food Red No. 3, Food Red No. 102, Food Red No. 104, Food Red No. 105, Food Red No. 106, edible lake color, red iron oxide, turmeric extract, riboflavin, riboflavin sodium phosphate, carotene liquid, tar color, and caramel.

[0037] These conventional additives can be used alone or in combination of two or more. The ratio of the conventional additives may be 50 parts by mass or less (e.g., 0.1 to 50 parts by mass) relative to 100 parts by mass of the medicinal ingredient, for example, 30 parts by mass or less, preferably 20 parts by mass or less, and more preferably 10 parts by mass or less.

[0038] The shape of the spherical core is not particularly limited as long as it is spherical, and the sphericity (sphericity) may be 0.6 or more (e.g., about 0.6 to 0.99), for example, 0.7 or more (e.g., 0.7 to 0.98), preferably 0.8 or more, more preferably 0.9 or more, and most preferably 0.95 or more. If the sphericity is too small, it may be difficult to form a uniform coat portion.

[0039] The central particle diameter of the spherical core (D 50 ) may be 250 μm or less (e.g., 10 to 250 μm), for example, 50 to 210 μm, preferably 100 to 200 μm, more preferably 130 to 180 μm, and most preferably 140 to 160 μm. If the central particle size of the spherical core is too small, there is a risk of reduced efficacy, whereas if it is too large, there is a risk of reduced formulation designability and reduced feeling of ingestion depending on the application.

[0040] In this specification and claims, the median particle size (D 50 ) and other particle sizes can be measured on a volume basis using a laser diffraction particle size analyzer. 50 means the particle size of the particles that constitutes 50% by volume of the cumulative total from the small particle side of the particle size distribution.

[0041] [Release control layer] The medicinal particle of the present invention further comprises a coating portion that covers the spherical core portion, and this coating portion comprises a release-controlling layer.

[0042] The release-controlling layer may be any layer capable of controlling the release of the active ingredient (esomeprazole), and may be a sustained-release layer that controls the release rate or a migration-controlling layer that controls migration, but is preferably an enteric layer (enteric coating layer) that is insoluble in gastric juice and soluble in intestinal juice.

[0043] The enteric layer contains an enteric polymer. As the enteric polymer, a conventional enteric polymer can be used. Examples of conventional enteric polymers include cellulose derivatives such as cellulose phthalate, cellulose acetate phthalate, hydroxypropyl cellulose phthalate, hydroxypropyl methylcellulose phthalate (HPMCF), and hydroxypropyl methylcellulose acetate succinate; (meth)acrylic polymers such as methacrylic acid-ethyl acrylate copolymer (methacrylic acid copolymer LD), methacrylic acid-n-butyl acrylate copolymer, and methacrylic acid-methyl methacrylate copolymer (methacrylic acid copolymer L, S); and polyvinyl acetate phthalate. These enteric polymers can be used alone or in combination of two or more. Among these, (meth)acrylic copolymers such as methacrylic acid copolymer LD and ethyl acrylate-methyl methacrylate copolymer are preferred.

[0044] The proportion of the enteric polymer in the enteric layer may be 10% by mass or more, for example, 30 to 95% by mass, preferably 50 to 90% by mass, more preferably 60 to 85% by mass, and most preferably 70 to 80% by mass. If the proportion of the enteric polymer is too low, there is a risk of reduced enteric properties and bioavailability.

[0045] The enteric layer may further contain a plasticizer in addition to the enteric polymer. Examples of the plasticizer include those exemplified in the section on the spherical core. The plasticizers may be used alone or in combination of two or more. Among the plasticizers, fat-soluble plasticizers such as triethyl citrate are preferred.

[0046] The proportion of the plasticizer is, for example, 5 to 80 parts by mass, preferably 10 to 50 parts by mass, more preferably 20 to 40 parts by mass, and most preferably 30 to 35 parts by mass, relative to 100 parts by mass of the enteric polymer. If the proportion of the plasticizer is too low, it may be difficult to form a uniform enteric layer, and conversely, if it is too high, the enteric properties may decrease.

[0047] The enteric layer may further contain a surfactant in addition to the enteric polymer. Examples of the surfactant include those exemplified in the section on the spherical core portion. The surfactants may be used alone or in combination of two or more. Among the surfactants, glycerin fatty acid esters and polysorbates are preferred, and glycerin mono-C such as glycerin monostearate is preferred. 8-24 Fatty acid esters are particularly preferred.

[0048] The proportion of the surfactant is, for example, 1 to 30 parts by mass, preferably 2 to 20 parts by mass, more preferably 3 to 10 parts by mass, and most preferably 4 to 8 parts by mass, relative to 100 parts by mass of the enteric polymer. If the proportion of the surfactant is too low, it may be difficult to form a uniform enteric layer, and conversely, if it is too high, the enteric properties may decrease.

[0049] The enteric layer may further contain a lubricant in addition to the enteric polymer. Examples of the lubricant include the lubricants exemplified in the section on the spherical core. The lubricants may be used alone or in combination of two or more. Among the lubricants, silicon oxide such as hydrated silicon dioxide is preferred.

[0050] The proportion of the lubricant is, for example, 0.01 to 3 parts by mass, preferably 0.05 to 1 part by mass, and more preferably 0.1 to 0.5 part by mass, relative to 100 parts by mass of the enteric polymer.

[0051] The enteric layer may further contain other additives in addition to the enteric polymer. Examples of other additives include excipients, binders, disintegrants, pH adjusters, colorants, sweeteners or flavorings, flavorings or fragrances, refreshing agents, antioxidants, preservatives or preservatives, wetting agents, antistatic agents, disintegration aids, etc., as exemplified in the section on the spherical core. These additives can be used alone or in combination of two or more. The total proportion of these additives is, for example, 10 parts by mass or less (for example, 0.1 to 10 parts by mass), preferably 5 parts by mass or less, relative to 100 parts by mass of the enteric polymer.

[0052] The release-controlling layer (particularly, the enteric layer) may be a single layer or a combination of multiple layers. The combination of multiple layers may be two or more layers, for example, 2 to 4 layers. In the case of a combination of multiple layers, an intermediate layer described below may be interposed between the enteric layers (for example, in the case of two layers, between the first enteric layer and the second enteric layer). Among these, the combination of multiple layers is preferred, the combination of 2 to 3 layers is more preferred, and the combination of 2 layers is most preferred, from the viewpoint that cracks are likely to occur in the orally disintegrating tablet and the effect of the present invention is likely to be exhibited.

[0053] The proportion of the release-controlling layer (particularly the enteric layer) (proportion of each layer in the case of a combination of multiple layers) is, for example, 30 to 200 parts by mass, preferably 50 to 150 parts by mass, more preferably 80 to 100 parts by mass, and most preferably 90 to 95 parts by mass, relative to 100 parts by mass of the spherical core. If the proportion of the release-controlling layer is too low, the release controllability may decrease, whereas if it is too high, the formulation designability may decrease.

[0054] The average thickness of the release-controlling layer (particularly the enteric layer) (in the case of a combination of multiple layers, the average thickness of each layer) is, for example, 10 to 40 μm, preferably 15 to 35 μm, and more preferably 20 to 30 μm.

[0055] [Middle layer] The intermediate layer interposed between the multiple release control layers may contain a binder. Examples of the binder include the binders exemplified in the section on the spherical core. The binders may be used alone or in combination of two or more. Among the binders, hydroxy C such as hypromellose is preferred. 2-4 Alkyl C 1-2 Alkyl cellulose is preferred. By interposing an intermediate layer between a plurality of release-controlling layers (particularly, enteric layers), the control function of the release-controlling layer can be adjusted.

[0056] The intermediate layer may further contain an excipient in addition to the binder. Examples of the excipient include the excipients exemplified in the section on the spherical core, as well as silicic acids such as talc, light anhydrous silicic acid, hydrated silicon dioxide (hydrated anhydrous silicic acid), calcium silicate, magnesium silicate, synthetic aluminum silicate, and magnesium aluminometasilicate; metal oxides such as magnesium oxide and titanium oxide; carbonates such as precipitated calcium carbonate and magnesium carbonate; lactates such as calcium lactate; phosphates such as anhydrous calcium hydrogen phosphate and calcium monohydrogen phosphate; and minerals such as bentonite, synthetic hydrotalcite, and kaolin. These excipients can be used alone or in combination of two or more. Among these, silicates such as talc are preferred.

[0057] The ratio of the excipient is, for example, 30 to 200 parts by mass, preferably 50 to 150 parts by mass, and more preferably 90 to 100 parts by mass, relative to 100 parts by mass of the binder. If the ratio of the excipient is too low, the mechanical properties of the intermediate layer may be reduced, whereas if the ratio is too high, the interlayer adhesion may be reduced.

[0058] The intermediate layer may further contain a lubricant in addition to the binder. Examples of the lubricant include the lubricants exemplified in the section on the spherical core (excluding talc and hydrous silicon dioxide). The lubricants may be used alone or in combination of two or more. Among the lubricants, silicon oxides such as hydrous silicon dioxide are preferred.

[0059] The proportion of the lubricant is, for example, 0.1 to 10 parts by mass, preferably 0.5 to 5 parts by mass, and more preferably 1 to 3 parts by mass, relative to 100 parts by mass of the binder.

[0060] The intermediate layer may further contain other additives in addition to the binder. Examples of other additives include disintegrants, plasticizers, surfactants, pH adjusters, colorants, sweeteners or flavorings, flavorings or fragrances, refreshing agents, antioxidants, preservatives or preservatives, wetting agents, antistatic agents, and disintegration aids, which are exemplified in the section on the spherical cores. These additives can be used alone or in combination of two or more. The total proportion of these additives is, for example, 10 parts by mass or less (for example, 0.1 to 10 parts by mass), and preferably 5 parts by mass or less, relative to 100 parts by mass of the binder.

[0061] The ratio of the intermediate layer (the ratio of each layer in the case of a combination of multiple layers) is, for example, 1 to 100 parts by mass, preferably 3 to 80 parts by mass, more preferably 5 to 50 parts by mass, and most preferably 10 to 30 parts by mass, relative to 100 parts by mass of the spherical core. If the ratio of the intermediate layer is too low, the mechanical properties of the enteric layer may be reduced, whereas if it is too high, the ease of formulation design may be reduced.

[0062] The average thickness of the intermediate layer (the average thickness of each layer in the case of a combination of multiple layers) is, for example, 1 to 15 μm, preferably 2 to 10 μm, and more preferably 3 to 8 μm. If the thickness of the intermediate layer is too thin, the mechanical properties of the enteric layer may be reduced, whereas if it is too thick, the formulation designability may be reduced.

[0063] [Shielding layer] The coating part may further include a shielding layer interposed between the spherical core and the release-controlling layer in addition to the release-controlling layer. The components of the release-controlling layer (especially the enteric polymer of the enteric layer) have functional groups such as carboxyl groups, so that by interposing a shielding layer between the release-controlling layer and the spherical core, the efficacy of the medicinal ingredient in the spherical core can be prevented from being reduced by the functional groups. This shielding layer may be the first shielding layer, as described later.

[0064] (First shielding layer) The shielding layer (first shielding layer) contains an excipient (first excipient). Examples of the excipient include the excipients exemplified in the section on the intermediate layer. Among these, silicates such as talc and metal oxides such as titanium oxide are preferred, and a combination of silicates and metal oxides is particularly preferred.

[0065] The proportion of the excipient in the shielding layer may be 10% by mass or more, for example, about 30 to 95% by mass, preferably about 50 to 93% by mass, more preferably about 70 to 90% by mass, and most preferably about 75 to 85% by mass. If the proportion of the excipient is too low, there is a risk of the medicinal effect being reduced.

[0066] The shielding layer (first shielding layer) may further contain a binder in addition to the excipient. Examples of the binder include the binders exemplified in the section on the spherical core portion. The binders may be used alone or in combination of two or more. Among the binders, hydroxypropylcellulose and other hydroxypropylcellulose are preferred. 2-4 Alkylcelluloses are preferred.

[0067] The proportion of the binder is, for example, 3 to 100 parts by mass, preferably 5 to 50 parts by mass, more preferably 10 to 30 parts by mass, and most preferably 15 to 25 parts by mass, relative to 100 parts by mass of the excipient. If the proportion of the binder is too low, the mechanical properties of the shielding layer may be reduced, whereas if the proportion is too high, the medicinal effect may be reduced.

[0068] The shielding layer (first shielding layer) may further contain a lubricant in addition to the excipient. Examples of the lubricant include the lubricants exemplified in the section on the spherical core portion (excluding talc and hydrous silicon dioxide). The lubricants can be used alone or in combination of two or more. Among the lubricants, fatty acid metal salts such as magnesium stearate and silicon oxides such as hydrous silicon dioxide are preferred, and C 8-24 A combination of a fatty acid metal salt and silicon oxide is particularly preferred.

[0069] The proportion of the lubricant is, for example, 1 to 20 parts by mass, preferably 2 to 10 parts by mass, and more preferably 3 to 8 parts by mass, relative to 100 parts by mass of the excipient.

[0070] The shielding layer (first shielding layer) may further contain other additives in addition to the excipient. Examples of other additives include disintegrants, plasticizers, surfactants, pH adjusters, colorants, sweeteners or flavorings, flavorings or fragrances, refreshing agents, antioxidants, preservatives or preservatives, wetting agents, antistatic agents, and disintegration aids, which are exemplified in the section on the spherical core. These additives can be used alone or in combination of two or more. The total proportion of these additives is, for example, 10 parts by mass or less (for example, 0.1 to 10 parts by mass), and preferably 5 parts by mass or less, relative to 100 parts by mass of the excipient.

[0071] The ratio of the shielding layer (first shielding layer) is, for example, 30 to 150 parts by mass, preferably 50 to 120 parts by mass, more preferably 70 to 100 parts by mass, and most preferably 80 to 90 parts by mass, relative to 100 parts by mass of the spherical core. If the ratio of the shielding layer is too low, the efficacy may decrease, whereas if it is too high, the formulation designability may decrease.

[0072] The average thickness of the shielding layer (first shielding layer) is, for example, 10 to 40 μm, preferably 15 to 35 μm, and more preferably 20 to 30 μm. If the shielding layer is too thin, the efficacy may decrease, whereas if it is too thick, the formulation designability may decrease.

[0073] The shielding layer may be a single layer such as this, but a combination of multiple shielding layers is preferred in that it improves the strength of the shielding layer, reduces the likelihood of cracking in the orally disintegrating tablet, and makes it easier to achieve the effects of the present invention. In particular, a combination of a first shielding layer formed with the shielding layer and a second shielding layer formed on the enteric layer side (a second shielding layer laminated on the first shielding layer) is preferred.

[0074] (Second shielding layer) The second shielding layer contains an excipient (second excipient). Examples of the second excipient include the excipients exemplified in the section on the intermediate layer. Among the excipients, silicates such as talc are preferred.

[0075] The proportion of the second excipient in the second shielding layer may be 10% by mass or more, for example, 10 to 90% by mass, preferably 30 to 85% by mass, more preferably 50 to 80% by mass, and most preferably about 60 to 70% by mass. If the proportion of the second excipient is too low, there is a risk of the medicinal effect being reduced.

[0076] The second shielding layer may further contain a binder in addition to the second excipient. Examples of the binder include the binders exemplified in the section on the spherical core. The binders may be used alone or in combination of two or more. Among the binders, hydroxypropylcellulose and other hydroxypropylcellulose are preferred. 2-4 Alkylcelluloses are preferred.

[0077] The proportion of the binder is, for example, 5 to 100 parts by mass, preferably 10 to 80 parts by mass, more preferably 20 to 70 parts by mass, and most preferably 30 to 50 parts by mass, relative to 100 parts by mass of the second excipient. If the proportion of the binder is too low, the mechanical properties of the second shielding layer may be reduced, whereas if the proportion is too high, the medicinal effect may be reduced.

[0078] The second shielding layer may further contain a lubricant in addition to the second excipient. Examples of the lubricant include the lubricants exemplified in the section on the spherical core portion (excluding talc and hydrous silicon dioxide). The lubricants may be used alone or in combination of two or more. Among the lubricants, fatty acid metal salts such as magnesium stearate and silicon oxides such as hydrous silicon dioxide are preferred, and C 8-24 A combination of a fatty acid metal salt and silicon oxide is particularly preferred.

[0079] The proportion of the lubricant is, for example, 1 to 20 parts by mass, preferably 3 to 15 parts by mass, and more preferably 5 to 10 parts by mass, relative to 100 parts by mass of the second excipient.

[0080] The second shielding layer may further contain other additives in addition to the second excipient. Examples of other additives include disintegrants, plasticizers, surfactants, pH adjusters, colorants, sweeteners or flavorings, flavorings or fragrances, refreshing agents, antioxidants, preservatives or preservatives, wetting agents, antistatic agents, and disintegration aids, which are exemplified in the section on the spherical core. These additives can be used alone or in combination of two or more. The total proportion of these additives is, for example, 10 parts by mass or less (for example, 0.1 to 10 parts by mass), preferably 5 parts by mass or less, relative to 100 parts by mass of the second excipient.

[0081] The proportion of the second shielding layer is, for example, 3 to 80 parts by mass, preferably 5 to 50 parts by mass, more preferably 10 to 30 parts by mass, and most preferably 20 to 25 parts by mass, relative to 100 parts by mass of the spherical core. If the proportion of the second shielding layer is too low, the effect of reinforcing the first shielding layer may decrease, whereas if it is too high, the ease of formulation design may decrease.

[0082] The average thickness of the second shielding layer is, for example, 1 to 15 μm, preferably 2 to 10 μm, and more preferably 3 to 8 μm. If the thickness of the second shielding layer is too thin, the effect of reinforcing the first shielding layer may be reduced, whereas if the thickness is too thick, the formulation designability may be reduced.

[0083] [Outermost layer] The outermost layer of the coating portion contains mannitol in an amount of 4% by mass or more in the medicinal particles, and in the present invention, the surface of the medicinal particles contains mannitol at a specific ratio, so that the occurrence of cracks in the tablet itself can be suppressed even when the tablet is compressed to prepare an orally disintegrating tablet. Although the reason why the outermost layer suppresses the occurrence of cracks is not clear, it can be presumed that the outermost layer containing mannitol at a specific ratio absorbs stress, thereby suppressing the occurrence of voids around the medicinal particles due to plastic deformation even when the medicinal particles have high hardness.

[0084] As the mannitol, D-mannitol is preferred. The angle of repose of mannitol is, for example, 30 to 70°, preferably 40 to 65°, more preferably 45 to 60°, and most preferably 50 to 55°. If the angle of repose is too small, the mechanical properties of the rapidly disintegrating particles may be reduced, whereas if it is too large, the oral disintegrability may be reduced.

[0085] In this specification and claims, the angle of repose can be measured in accordance with JIS R9301-2-2.

[0086] The proportion of mannitol contained in the outermost layer may be 4% by mass or more (for example, about 4 to 30% by mass) in the medicinal particles, but from the viewpoints of suppressing cracking of the tablets and increasing productivity, it is preferably 5 to 25% by mass, even more preferably 7 to 20% by mass, even more preferably 8 to 15% by mass, and most preferably 9 to 12% by mass.

[0087] The proportion of mannitol in the outermost layer may be 50% by mass or more, for example, 80% by mass or more (80 to 100% by mass), preferably 90 to 99.99% by mass, more preferably 95 to 99.9% by mass, and most preferably 98 to 99.5% by mass. If the proportion of mannitol is too low, there is a risk that formulation designability will decrease.

[0088] The outermost layer may further contain, in addition to mannitol, a colorant exemplified in the section on the spherical core portion. The colorants may be used alone or in combination of two or more. Among the colorants, yellow ferric oxide and ferric oxide are preferred.

[0089] The proportion of the colorant is, for example, 0.01 to 5 parts by mass, preferably 0.05 to 3 parts by mass, more preferably 0.1 to 2 parts by mass, and most preferably 0.5 to 1.5 parts by mass, relative to 100 parts by mass of mannitol.

[0090] The outermost layer may further contain other sugar alcohols in addition to mannitol. Examples of other sugar alcohols include sorbitol, mannitol, reduced maltose syrup (maltitol), reduced starch syrup, xylitol, reduced palatinose, and 4-carbon sugars obtained by fermenting glucose (e.g., erythritol, etc.). The ratio of other sugar alcohols is, for example, 50 parts by mass or less (e.g., 0.1 to 50 parts by mass), preferably 30 parts by mass or less, and more preferably 10 parts by mass or less, relative to 100 parts by mass of mannitol.

[0091] The outermost layer may further contain other additives in addition to mannitol. Examples of other additives include excipients, binders, plasticizers, surfactants, pH adjusters, sweeteners or flavorings, flavorings or fragrances, refreshing agents, antioxidants, preservatives or preservatives, wetting agents, antistatic agents, disintegration aids, etc., as exemplified in the section on the spherical core. These additives can be used alone or in combination of two or more. The total proportion of these additives is, for example, 10 parts by mass or less (e.g., 0.1 to 10 parts by mass), preferably 5 parts by mass or less, relative to 100 parts by mass of mannitol.

[0092] The outermost layer is preferably substantially free of a disintegrant, particularly preferably free of a disintegrant, such as those exemplified in the section on the spherical core, and is preferably free of low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, and sodium croscarmellose.

[0093] The ratio of the outermost layer is, for example, 15 to 100 parts by mass, preferably 20 to 80 parts by mass, more preferably 30 to 60 parts by mass, and most preferably 40 to 50 parts by mass, relative to 100 parts by mass of the spherical core. If the ratio of the outermost layer is too low, cracks may occur, whereas if it is too high, formulation designability may decrease.

[0094] The average thickness of the outermost layer is, for example, 1 to 15 μm, preferably 2 to 10 μm, and more preferably 3 to 8 μm. If the thickness of the outermost layer is too thin, cracks may occur, whereas if it is too thick, formulation designability may decrease.

[0095] [Characteristics and manufacturing method of medicinal particles] The medicinal particles of the present invention may have high particle hardness. In the present invention, even if the medicinal particles have high hardness, the occurrence of cracks in the tablet can be suppressed even when an orally disintegrating tablet containing the functional particles is produced by tableting.

[0096] The particle hardness of the medicinal particles of the present invention may be 350 gf or more (particularly 400 gf or more), for example, 400 to 600 gf, preferably 450 to 550 gf, more preferably 470 to 530 gf, and most preferably 480 to 520 gf. If the particle hardness is too low, the occurrence of cracks is suppressed, and there is a risk that the effects of the present invention will not be fully exerted.

[0097] In the present specification and claims, the particle hardness can be measured using a conventional texture analyzer, and more specifically, can be measured by the method described in the Examples.

[0098] The median particle size (D 50 ) is, for example, 460 to 550 μm, preferably 470 to 530 μm, more preferably 490 to 520 μm, and most preferably 495 to 510 μm. If the particle size is too small, the effects of the present invention may not be fully exerted, whereas if it is too large, formulation designability may be reduced.

[0099] The medicinal particles of the present invention can be produced by coating a spherical core with a coating portion.

[0100] The method for preparing the spherical core can be appropriately selected depending on the type of the spherical core, and may be a conventional method. When the spherical core is a complex (a complex in which the surface of a spherical excipient is coated with a composition containing a medicinal ingredient), the spherical core may be coated with a composition containing a medicinal ingredient by a conventional coating method. Examples of conventional coating methods include application, spraying, impregnation / immersion, pan coating, fluidized bed coating, rolling coating, and rolling fluidized coating. Among these, fluidized bed coating and rolling fluidized coating are preferred, and rolling fluidized coating is particularly preferred.

[0101] The coating method of the coated portion can also be the above-mentioned conventional method, and fluidized bed coating and rolling fluidized coating are preferred, with rolling fluidized coating being particularly preferred. The coated portion may be coated by a different coating method for each layer, or all layers may be coated by the same method. From the viewpoint of productivity, etc., it is preferred to coat all layers by the same coating method, and it is particularly preferred to coat all layers by rolling fluidized coating.

[0102] [Orucodisintegrating tablet] The orally disintegrating tablet (OD tablet) of the present invention may contain the medicinal particles, but in order to improve oral disintegrability, an OD tablet obtained by compressing a composition for OD tablets containing the medicinal particles and rapidly disintegrating particles is preferred.

[0103] (Fast-disintegrating particles) The rapidly disintegrating particles contained in the OD tablet may be formed of a composition containing a disintegrant, and may be rapidly disintegrating particles used as rapidly disintegrating particles for OD tablets. The rapidly disintegrating particles may contain a medicinal ingredient, but from the viewpoint of formulation design, etc., particles that do not contain a medicinal ingredient are preferred, and from the viewpoint of suppressing the occurrence of cracks and improving oral disintegrability and feeling of taking, rapidly disintegrating particles that contain sugar alcohol and carmellose and have a crystalline cellulose ratio of less than 1% by mass in the particles are particularly preferred.

[0104] Sugar alcohols are blended as excipients. Examples of sugar alcohols include sorbitol, mannitol, reduced maltose syrup (maltitol), reduced starch syrup, xylitol, reduced palatinose, and 4-carbon sugars obtained by fermenting glucose (e.g., erythritol, etc.). These sugar alcohols can be used alone or in combination of two or more. Among these, mannitol, sorbitol, erythritol, xylitol, etc. are commonly used, with mannitol being preferred, and D-mannitol being particularly preferred.

[0105] The shape of the sugar alcohol (raw sugar alcohol) is not particularly limited and may be amorphous, fibrous, ellipsoidal, spherical, tabular, granular, or the like, and is usually amorphous or granular.

[0106] Average particle size of sugar alcohol (raw sugar alcohol) (D 50 ) is, for example, 1 to 350 μm, preferably 5 to 250 μm, and more preferably 20 to 150 μm. If the particle size of the sugar alcohol is too small, the mechanical properties of the rapidly disintegrating particles may be reduced, whereas if it is too large, the feeling of taking the drug may be reduced.

[0107] The proportion of sugar alcohol (particularly mannitol) in the rapidly disintegrating particles may be 30% by mass or more, for example, 30 to 95% by mass, preferably 50 to 90% by mass, further preferably 60 to 85% by mass, more preferably 65 to 80% by mass, and most preferably 70 to 75% by mass. If the proportion of sugar alcohol is too low, there is a risk of the feeling of taking the tablet being reduced, whereas if the proportion is too high, there is a risk of the oral disintegration property being reduced.

[0108] The rapidly disintegrating particles further contain carmellose as a disintegrant in addition to sugar alcohol. In the rapidly disintegrating particles, by combining sugar alcohol with carmellose without substantially containing crystalline cellulose, not only the oral disintegration property but also the feeling of taking the tablet can be improved. In particular, by combining sugar alcohol with ethyl cellulose, silicic acid and crospovidone, which will be described later, the water conductivity of carmellose shows a synergistic effect with other ingredients, and therefore the oral disintegration property and feeling of taking the tablet can be highly improved, and the mechanical properties required for an orally disintegrating tablet can be ensured.

[0109] In the present specification and claims, the acid conversion rate means the ratio of the number of moles of free carboxyl groups to the total number of moles of free carboxyl groups and carboxyl groups that have formed salts, and can be measured by a conventional method such as acid or alkali titration or nuclear magnetic resonance spectroscopy.

[0110] In carmellose, the average degree of substitution (or average degree of etherification) of the carboxymethyl group is, for example, 0.1 to 1, preferably 0.2 to 0.8, more preferably 0.3 to 0.7, and most preferably 0.4 to 0.6. If the average degree of substitution is too low, there is a risk of the oral disintegration property decreasing. Note that this average degree of substitution is the average value of the degree of substitution (substitution ratio) for the hydroxyl group at the 6-position of the glucose unit constituting cellulose, and the maximum value is 1.

[0111] The shape of carmellose (raw carmellose) is not particularly limited and may be amorphous, fibrous, ellipsoidal, spherical, flat, granular, etc., and is usually amorphous, granular, etc.

[0112] Average particle size (D 50 ) is, for example, 1 to 70 μm, preferably 3 to 50 μm, and more preferably 5 to 30 μm. If the particle size of carmellose is too small, there is a risk that the oral disintegration property will decrease, whereas if it is too large, there is a risk that the feeling of taking the tablet will decrease.

[0113] The bulk density of carmellose is, for example, 100 to 800 g / liter, preferably 200 to 500 g / liter, and more preferably 300 to 400 g / liter.

[0114] The proportion of carmellose can be selected from the range of about 1 to 100 parts by mass relative to 100 parts by mass of sugar alcohol, for example, 3 to 50 parts by mass, preferably 5 to 45 parts by mass, more preferably 10 to 40 parts by mass, more preferably 20 to 35 parts by mass, and most preferably 25 to 30 parts by mass. The proportion of carmellose in the particles may be 3 to 50% by mass, preferably 5 to 40% by mass, more preferably 10 to 30% by mass, and most preferably 15 to 25% by mass. If the proportion of carmellose is too low, there is a risk of reduced oral disintegration, and conversely, if it is too high, there is a risk of reduced comfort when taken.

[0115] The rapidly disintegrating particles may further contain ethyl cellulose as a binder in addition to the sugar alcohol and carmellose.

[0116] The shape of the ethyl cellulose is not particularly limited and may be amorphous, fibrous, ellipsoidal, spherical, tabular, granular, or the like, and is usually amorphous or granular.

[0117] Average particle size of ethyl cellulose (D 50 ) is, for example, 1 to 60 μm, preferably 3 to 45 μm, and more preferably 5 to 15 μm. If the particle size of the ethyl cellulose is too small, the mechanical properties of the rapidly disintegrating particles may be reduced, whereas if it is too large, the feeling of taking the drug may be reduced.

[0118] The proportion of ethyl cellulose is, for example, 0.1 to 10 parts by mass, preferably 1 to 5 parts by mass, more preferably 1.5 to 4 parts by mass, and most preferably 2 to 3.5 parts by mass, relative to 100 parts by mass of sugar alcohol. The proportion of ethyl cellulose in the rapidly disintegrating particles may be 0.1 to 10% by mass, preferably 0.5 to 5% by mass, more preferably 1 to 3% by mass, and most preferably 1.5 to 2.5% by mass. If the proportion of ethyl cellulose is too low, the mechanical properties of the particles may be reduced, and conversely, if the proportion is too high, the oral disintegrability may be reduced.

[0119] The rapidly disintegrating particles may further contain silicic acid as a binder and / or disintegrant in addition to sugar alcohol and carmellose. Silicic acid is generally used as an excipient, but in the present invention, by combining with sugar alcohol and carmellose, it contributes to the improvement of hardness as well as the disintegration property in the oral cavity and the feeling of taking it, and by selecting silicic anhydride, it is possible to highly improve the disintegration property in the oral cavity and the feeling of taking it, probably because of the improvement of water conductivity.

[0120] Examples of silicic acids include the silicic acids exemplified as excipients in the section on the intermediate layer. The silicic acids can be used alone or in combination of two or more. Among these, silicic anhydride is preferred, and light silicic anhydride is particularly preferred.

[0121] The shape of the silicic acid (raw silicic acid) is not particularly limited and may be amorphous, fibrous, ellipsoidal, spherical, tabular, granular, or the like, and is usually amorphous or granular.

[0122] The average particle size (D 50 ) is, for example, 0.1 to 30 μm, preferably 0.5 to 10 μm, more preferably 1 to 5 μm, and most preferably 2 to 4 μm. If the particle size of the silicic acid is too small, there is a risk that the oral disintegration property will decrease, and conversely, if it is too large, there is a risk that the feeling of taking it will decrease.

[0123] The BET specific surface area of ​​silicic acid (raw silicic acid) is, for example, 50 to 1000 m2 / g, preferably 100 to 500m 2 / g, more preferably 150 to 450 m 2 / g, most preferably 200 to 400m 2 If the specific surface area is too small, the hardness may decrease, whereas if it is too large, the oral disintegrability may decrease.

[0124] The proportion of silicic acid is, for example, 0.1 to 10 parts by mass, preferably 0.3 to 5 parts by mass, more preferably 0.5 to 3 parts by mass, and most preferably 1 to 2 parts by mass, relative to 100 parts by mass of sugar alcohol. The proportion of silicic acid may be 0.1 to 5% by mass in the particles, preferably 0.3 to 3% by mass, more preferably 0.5 to 2% by mass, and most preferably 0.5 to 1.5% by mass. If the proportion of silicic acid is too low, the effect of improving hardness and disintegration in the oral cavity may decrease, and conversely, if the proportion is too high, the feeling of taking the tablet may decrease.

[0125] The rapidly disintegrating particles may further contain crospovidone as a disintegrant in addition to sugar alcohol and carmellose.

[0126] The shape of crospovidone (raw crospovidone) is not particularly limited and may be amorphous, fibrous, ellipsoidal, spherical, tabular, granular, or the like, and is usually amorphous or granular.

[0127] The average particle size of crospovidone (D 50 ) is, for example, 0.5 to 50 μm, preferably 1 to 30 μm, more preferably 3 to 20 μm, and most preferably 5 to 10 μm. If the particle size of crospovidone is too small, there is a risk that the oral disintegration property will decrease, whereas if it is too large, there is a risk that the feeling of taking the tablet will decrease.

[0128] The proportion of crospovidone is, for example, 3 to 20 parts by mass, preferably 5 to 15 parts by mass, more preferably 6 to 10 parts by mass, and most preferably 7 to 9 parts by mass, relative to 100 parts by mass of sugar alcohol. The proportion of crospovidone in the particles may be 3 to 15% by mass, preferably 5 to 10% by mass, more preferably 5 to 8% by mass, and most preferably 6 to 7% by mass. If the proportion of crospovidone is too low, there is a risk of the oral disintegration property decreasing, whereas if it is too high, there is a risk of the mechanical properties of the particles decreasing.

[0129] The rapidly disintegrating particles may further contain conventional additives that are incorporated into oral preparations, such as disintegrants (excluding crospovidone), excipients (excluding sugar alcohols and ethyl cellulose), binders (excluding carmellose), lubricants, plasticizers, surfactants, pH adjusters, colorants, sweeteners or flavorings, flavorings or refreshing agents, antioxidants, preservatives or preservatives, wetting agents, antistatic agents, disintegration aids, etc., as exemplified in the section on the spherical core.

[0130] These additives may be used alone or in combination of two or more. These additives may be present in an amount of 50% by mass or less (e.g., 0.01 to 50% by mass) in the rapidly disintegrating particles, for example, 30% by mass or less, preferably 20% by mass or less, more preferably 10% by mass or less, and most preferably 5% by mass or less (e.g., 0.1 to 5% by mass).

[0131] In order to achieve both oral disintegration and feeling of taking, it is preferable that the rapidly disintegrating particles do not substantially contain microcrystalline cellulose or crystalline cellulose.Therefore, the proportion of crystalline cellulose in the rapidly disintegrating particles is less than 1% by mass, preferably 0.5% by mass or less, more preferably 0.1% by mass or less, more preferably 0.01% by mass or less, and most preferably does not contain crystalline cellulose.If crystalline cellulose is contained in the rapidly disintegrating particles, both oral disintegration and feeling of taking are reduced.

[0132] From the viewpoint of achieving both oral disintegrability and a good feeling when taken, the rapidly disintegrating particles preferably contain substantially no starches, and more preferably contain substantially no starch.

[0133] Examples of starches include starches such as corn starch and potato starch; and starch derivatives such as pregelatinized starch, partially pregelatinized starch, oxidized starch, dextrin, cyclodextrin, hydroxypropyl starch, carboxymethyl starch, and sodium carboxymethyl starch.

[0134] In the above-mentioned rapidly disintegrating particles, the proportion of starches (particularly, starches such as corn starch) in the rapidly disintegrating particles is less than 1% by mass, preferably 0.5% by mass or less, more preferably 0.1% by mass or less, even more preferably 0.01% by mass or less, and most preferably no starches are contained. When the rapidly disintegrating particles contain starches (particularly, starch), both the oral disintegration property and the feeling of taking the particles are reduced.

[0135] The shape of the rapidly disintegrating particles is not particularly limited and may be amorphous, fibrous, ellipsoidal, spherical, tabular, granular, or the like, with amorphous, granular, and spherical shapes being preferred, and isotropic shapes such as spheres being particularly preferred.

[0136] The average particle size of the rapidly disintegrating particles (D 50 ) is, for example, 10 to 200 μm, preferably 30 to 150 μm, more preferably 50 to 100 μm, and most preferably 70 to 80 μm. If the particle size of the rapidly disintegrating particles is too small, there is a risk that the oral disintegration property will decrease, and conversely, if it is too large, there is a risk that the feeling of taking the tablet will decrease.

[0137] The 10% by volume particle size of the rapidly disintegrating particles (D 10 ) is, for example, 1 μm or more (for example, 1 to 75 μm), preferably 5 μm or more (for example, 5 to 50 μm), further preferably 10 μm or more (for example, 10 to 40 μm), more preferably 20 μm or more (for example, 20 to 35 μm), and most preferably 25 μm or more (for example, 25 to 30 μm). 10If the particle size is too small, there is a risk that the oral disintegrability will decrease.

[0138] The 90% volume particle size (D 90 ) is, for example, 300 μm or less (for example, 80 to 300 μm), preferably 250 μm or less (for example, 100 to 250 μm), more preferably 200 μm or less (for example, 130 to 200 μm), and most preferably 180 μm or less (for example, 150 to 180 μm). 90 If it is too large, there is a risk that the feeling of taking the tablet may decrease.

[0139] In the composition for OD tablets, the ratio of the rapidly disintegrating particles is, for example, 10 to 1000 parts by mass, preferably 30 to 500 parts by mass, more preferably 50 to 300 parts by mass, more preferably 80 to 200 parts by mass, and most preferably 100 to 150 parts by mass, relative to 100 parts by mass of the medicinal particles. If the ratio of the rapidly disintegrating particles is too low, there is a risk that the oral disintegration property and the feeling of taking the drug may be reduced, and conversely, if the ratio is too high, there is a risk that the formulation designability may be reduced.

[0140] (Method of producing fast-disintegrating particles) The rapidly disintegrating particles can be obtained by granulation using a conventional granulation method, such as rolling granulation, fluidized bed granulation, mixing and stirring granulation, spray drying granulation, vibration granulation, etc. Among these, the fluidized bed granulation is preferred from the viewpoint of productivity, etc.

[0141] As the fluidized bed granulation method, a conventional method can be used, but when the rapidly disintegrating particles contain sugar alcohol, carmellose, ethyl cellulose, silicic acid and crospovidone, it is preferable to mix the ingredients other than crospovidone in a fluidized bed granulator in advance and granulate by spraying an aqueous dispersion (granulation liquid) containing crospovidone. By mixing solid sugar alcohol and solid carmellose, it becomes easy to prepare rapidly disintegrating particles that can achieve both oral disintegrability and a good feeling when taken.

[0142] The solvent contained in the granulation liquid is not particularly limited, but may be water or a lower alcohol (e.g., C ethanol, isopropanol, etc. 1-4In terms of safety, water and / or ethanol are preferred, with water being particularly preferred. The proportion of the solvent is, for example, 1,000 to 2,000 parts by mass, preferably 1,200 to 1,800 parts by mass, and more preferably 1,400 to 1,600 parts by mass, relative to 100 parts by mass of crospovidone.

[0143] (Other ingredients) The composition for OD tablets may further contain, in addition to the medicinal particles and the rapidly disintegrating particles, an excipient, a disintegrant, a flow agent, a lubricant, a sweetener or flavoring agent, a flavoring agent or a refreshing agent.

[0144] The excipient may further include the excipients exemplified in the section on the spherical core. The excipients may be used alone or in combination of two or more. Among the excipients, celluloses such as crystalline cellulose and alkyl celluloses such as ethyl cellulose are preferred, and alkyl celluloses are particularly preferred. The ratio of the excipient is, for example, 1 to 100 parts by mass, preferably 3 to 50 parts by mass, more preferably 5 to 40 parts by mass, and most preferably 10 to 30 parts by mass, relative to 100 parts by mass of the medicinal particles.

[0145] The disintegrant may further include the disintegrants exemplified in the section on the spherical core portion. The disintegrants may be used alone or in combination of two or more. Among the disintegrants, crosslinked polyvinylpyrrolidones such as crospovidone are preferred. The proportion of the disintegrant is, for example, 1 to 50 parts by mass, preferably 2 to 30 parts by mass, more preferably 3 to 20 parts by mass, and most preferably 5 to 15 parts by mass, relative to 100 parts by mass of the medicinal particles.

[0146] Examples of the fluidizing agent include talc, anhydrous silicic acid such as light anhydrous silicic acid, and silicic acids such as calcium silicate, magnesium silicate, synthetic aluminum silicate, and magnesium aluminometasilicate. Of the above fluidizing agents, anhydrous silicic acid such as light anhydrous silicic acid is preferred. The proportion of the fluidizing agent is, for example, 0.05 to 5 parts by mass, preferably 0.1 to 3 parts by mass, and more preferably 0.3 to 1 part by mass, relative to 100 parts by mass of the medicinal particles.

[0147] Examples of the lubricant include the lubricants exemplified in the section on the spherical core. The lubricants can be used alone or in combination of two or more. Among the lubricants, fatty acid metal salts such as magnesium stearate are preferred. The ratio of the lubricant is, for example, 0.05 to 5 parts by mass, preferably 0.1 to 3 parts by mass, and more preferably 0.3 to 1 part by mass, relative to 100 parts by mass of the medicinal particles.

[0148] The sweetener or flavoring agent may be any of those exemplified in the section on the spherical core portion. The proportion of the sweetener or flavoring agent is, for example, 0.1 to 5 parts by mass, preferably 0.5 to 3 parts by mass, and more preferably 1 to 2 parts by mass, relative to 100 parts by mass of the medicinal particles.

[0149] Examples of the flavoring agent or refreshing agent include those exemplified in the section on the spherical core portion. The proportion of the flavoring agent or refreshing agent is, for example, 0.01 to 3 parts by mass, preferably 0.05 to 1 part by mass, and more preferably 0.1 to 0.5 parts by mass, relative to 100 parts by mass of the medicinal particles.

[0150] The tablet diameter of the OD tablet of the present invention is, for example, 3 to 20 mm, preferably 5 to 15 mm, more preferably 7 to 12 mm, and most preferably 8 to 11 mm.

[0151] The method for producing the OD tablet of the present invention may be a method for tableting using such a composition for OD tablets, and a conventional method may be used. EXAMPLES

[0152] The present invention will be described in more detail below based on examples, but the present invention is not limited to these examples. The raw materials used in the following examples and the methods evaluated are shown below. The weights of the raw materials used are all solid weights.

[0153] [Evaluation method] (particle size distribution) Particle size distribution (D 50 ) was measured on a volume basis using a laser diffraction particle size distribution measuring device (manufactured by Malvern Instruments, trade name "Mastersizer 3000").

[0154] (particle hardness) The particle hardness was measured using a texture analyzer (manufactured by SMS, product name "Texture Analyzer TA.XT Plus") by compressing the granules under the conditions described below using a flat probe with a diameter of 3 mm as a tool, and the maximum pressure at which the granule broke and the pressure decreased was measured as the granule strength.

[0155] Load cell: 5kg Probe speed: 0.1mm / sec Trigger weight: 1g to 2000g compressed.

[0156] (Tablet hardness) The tablet hardness was measured using an ERWEKA tablet hardness tester (manufactured by ERWEKA, product name "Tablet Hardness Tester TBH425TD") by applying a load to the tablet with an indenter using a motorized weight load.

[0157] (Whether or not cracks occur) The side surface of the obtained orally disintegrating tablet was visually observed and evaluated.

[0158] Comparative Examples 1 to 6 [Preparation of medicinal particles] The medicinal particles were prepared by the following procedure. The mass per tablet of the raw materials used is shown in Table 1. The mass per tablet of the raw materials used in the outermost layer is shown in Table 2.

[0159] (Preparation of spherical core) 1) Lactose-crystalline cellulose spherical granules (manufactured by Freund Corporation, product name "Nonpareil-105 (Grade 150)") were placed into a tumbling fluidized bed granulator dryer.

[0160] 2) Purified water and ethanol (manufactured by Japan Alcohol Industry Co., Ltd., standard content 99.5% by volume) were mixed, and esomeprazole magnesium hydrate (manufactured by Aurobindo) and hypromellose (manufactured by Shin-Etsu Chemical Co., Ltd., product name "TC-5R") were dissolved / dispersed in the mixture, and the entire amount of this liquid was sprayed to coat the surface, followed by drying.

[0161] 3) The dried product was mixed with talc (manufactured by Nippon Talc Co., Ltd., product name "MICRO ACE P-3"), and the mixed powder was classified using a 30M sieve and a 100M sieve. The particles that passed through the 30M sieve and remained on the 100M sieve were used as spherical cores.

[0162] (First shielding layer coating process) 1) The spherical cores were placed in a tumbling fluidized bed granulator dryer.

[0163] 2) Purified water and ethanol were mixed, and hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd., product name "HPC-SL") was dissolved in the mixture. Then, talc (MICRO ACE P-3) and magnesium stearate (manufactured by Taihei Chemical Industry Co., Ltd., grade "Vegetable (Taihei)") were dispersed therein to prepare dispersion A.

[0164] 3) Separately, titanium oxide (manufactured by Freund Corporation, product name "Titanium Oxide FG") was dispersed in purified water and filtered through a 100M sieve to prepare filtrate B.

[0165] 4) Dispersion A and filtrate B were mixed, and the entire amount of this mixture was sprayed onto the substrate to coat it, and then dried.

[0166] 5) The dried product was mixed with hydrated silicon dioxide (manufactured by Fuji Silysia Chemical, trade name "Adsolider-102"), and the mixed powder was classified using a 30M sieve and a 100M sieve. The particles that passed through the 30M sieve and remained on the 100M sieve were prepared as the first shielding layer coated particles.

[0167] (Coating process of second shielding layer) 1) The first shielding layer coated particles were placed in a tumbling fluidized bed granulation dryer.

[0168] 2) Purified water and ethanol were mixed, and hydroxypropyl cellulose (HPC-SL) was dissolved in the mixture. Then, talc (MICRO ACE P-3) and magnesium stearate (manufactured by Taihei Chemical Industry Co., Ltd., grade "Vegetable (Taihei)") were dispersed in the mixture. The entire amount of this liquid was sprayed to coat the surface, and then dried.

[0169] 3) The dried product was mixed with hydrated silicon dioxide (Adsolider-102), and the mixed powder was classified through a 30M sieve and a 100M sieve. The particles that passed through the 30M sieve and remained on the 100M sieve were prepared as second shielding layer coated particles.

[0170] (First enteric layer coating process) 1) The second shielding layer coated particles were placed in a tumbling fluidized bed granulator dryer.

[0171] 2) Methacrylic acid copolymer LD (Evonik, trade name "Eudragit L30D-55"), polysorbate 80 (Sanyo Chemical Industries, Ltd., trade name "Polysorbate 80"), triethyl citrate (Morimura Shoji, trade name "Citroflex 2 (SC-60)") and glycerin monostearate (Riken Vitamin, trade name "Glycerin Monostearate P-100 10K") were dispersed in purified water, mixed, and the liquid was filtered through a 100M sieve. The entire amount was sprayed onto the surface to coat and then dried.

[0172] 3) The dried product was mixed with hydrated silicon dioxide (Adsolider-102), and the mixed powder was classified through a 30M sieve and a 100M sieve. The particles that passed through the 30M sieve and remained on the 100M sieve were prepared as the first enteric layer-coated particles.

[0173] (Intermediate layer coating process) 1) The first enteric layer-coated particles were placed in a tumbling fluidized bed granulator dryer.

[0174] 2) Hypromellose (TC-5R) and talc (MICRO ACE P-3) were dissolved and dispersed in purified water, and the entire amount of this liquid was sprayed to coat the surface, followed by drying.

[0175] 3) The dried product was mixed with hydrated silicon dioxide (Adsolider-102), and the mixed powder was classified through a 30M sieve and a 100M sieve. The particles that passed through the 30M sieve and remained on the 100M sieve were prepared as intermediate layer-coated particles.

[0176] (Second enteric layer coating process) 1) The intermediate layer-coated particles were placed in a tumbling fluidized bed granulator dryer.

[0177] 2) Methacrylic acid copolymer LD (Eudragit L30D-55), polysorbate 80 (Sanyo Chemical Industries, Ltd.), triethyl citrate (SC-60) and glycerin monostearate (P-100 10K) were dispersed in purified water, mixed, and the mixture was filtered through a 100M sieve. The entire amount of the mixture was sprayed onto the surface to coat it, and then dried.

[0178] 3) The dried product was mixed with hydrated silicon dioxide (Adsolider-102), and the mixed powder was classified through a 22M sieve and a 100M sieve. The particles that passed through the 22M sieve and remained on the 100M sieve were used as the second enteric layer-coated particles.

[0179] (Outermost layer coating process) 1) The second enteric layer coated particles were placed in a tumbling fluidized bed granulator dryer.

[0180] 2) D-mannitol (manufactured by ROQUETTE, product name "PEARLITOL 50C") was dissolved in purified water, and then yellow ferric oxide (manufactured by Kishi Chemical Industries, Ltd.) and ferric oxide (manufactured by Kishi Chemical Industries, Ltd.) were dispersed therein. The filtrate was filtered through a 200M sieve, and the entire amount was sprayed onto the surface to coat it, followed by drying.

[0181] 3) The dried product was classified using a 22M sieve and a 100M sieve, and the particles that passed through the 22M sieve and remained on the 100M sieve were taken as medicinal particles. The median particle size (D 50) was 494 μm and the particle hardness was 484.5 gf.

[0182] [Table 1]

[0183] [Preparation of fast-disintegrating particles] The rapidly disintegrating particles were prepared according to the following procedure. The mass per tablet of the raw materials used is shown in Table 2.

[0184] 1) D-mannitol, ethyl cellulose, light anhydrous silicic acid and carmellose were placed in a fluidized bed granulator and granulated with a granulation liquid prepared by dispersing crospovidone in purified water, followed by drying to prepare rapidly disintegrating particles.

[0185] [Preparation of OD tablets] The OD tablets were prepared according to the following procedure. The masses of the raw materials used per tablet are shown in Table 2.

[0186] 1) Medicinal particles, rapidly disintegrating particles, crystalline cellulose (manufactured by Asahi Kasei Corporation, trade name "CEOLUS KG-802"), crospovidone (manufactured by BASF Japan, trade name "Kollidon CL-F", type A), ethyl cellulose (manufactured by The Dow Chemical Corporation, trade name "Ethocel Standard 7FP Premium"), aspartame (manufactured by Ajinomoto Co., Inc.), and flavoring were mixed, and magnesium stearate (manufactured by Taihei Chemical Industry Co., Ltd., grade "Vegetable (Taihei)") was further added and mixed to obtain a tablet powder.

[0187] 2) The obtained powder was compressed into tablets using a rotary tablet press to prepare OD tablets with a tablet diameter of 9 mm, a thickness of 5.4 mm, and a hardness of 60 N.

[0188] The evaluation results of the obtained OD tablets are shown in Table 2.

[0189] [Table 2]

[0190] As is clear from the results in Table 2, in Comparative Examples 1 to 6, cracks occurred when the agent diameter was small.

[0191] Examples 1 to 6 OD tablets were prepared in the same manner as in Comparative Examples 1 to 6, except that the amount of D-mannitol in the outermost layer of the medicinal particles was changed to the ratio shown in Table 3, and the composition of the rapidly disintegrating particles was also changed to the ratio shown in Table 3. The evaluation results of the obtained OD tablets are shown in Table 3.

[0192] [Table 3]

[0193] As is clear from the results in Table 3, in Examples 1 to 6, the occurrence of cracks could be suppressed over a wide range of agent diameters.

[0194] Examples 7 to 13 OD tablets were prepared in the same manner as in Comparative Examples 1 to 6, except that the amount of D-mannitol in the outermost layer of the medicinal particles was changed to the ratio shown in Table 4, and the composition of the rapidly disintegrating particles was also changed to the ratio shown in Table 4. The evaluation results of the obtained OD tablets are shown in Table 4.

[0195] [Table 4]

[0196] As is clear from the results in Table 4, in Examples 7 to 13, the occurrence of cracks could be suppressed over a wide range of agent diameters.

[0197] Examples 14 to 18 OD tablets were prepared in the same manner as in Comparative Examples 1 to 6, except that the amount of D-mannitol in the outermost layer of the medicinal particles was changed to the ratio shown in Table 5, and the composition of the rapidly disintegrating particles was also changed to the ratio shown in Table 5. The evaluation results of the obtained OD tablets are shown in Table 5.

[0198] [Table 5]

[0199] As is clear from the results in Table 5, in Examples 14 to 18, the occurrence of cracks could be suppressed over a wide range of agent diameters.

[0200] Examples 19 and 20 OD tablets having the compositions shown in Tables 6 and 7 were prepared in the same manner as in the Examples.

[0201] [Table 6]

[0202] [Table 7] [Industrial Applicability]

[0203] The medicinal particles of the present invention can be used as functional medicinal particles for preparing orally disintegrating tablets containing various medicinal ingredients, and are particularly suitable as functional medicinal particles for preparing orally disintegrating tablets containing medicinal ingredients that are easily decomposed by gastric fluid (gastric acid) and require an enteric layer.

Claims

1. A medicinal particle formed of a spherical core containing a medicinal ingredient and a coating part that covers the spherical core and includes a release control layer and an outermost layer containing mannitol, The proportion of the mannitol in the outermost layer is 95% by mass or more, The proportion of mannitol contained in the outermost layer is 4 to 15% by mass in the medicinal particle; and Medicinal particles having a particle hardness of 400 gf or more.

2. 2. The pharmaceutical particle according to claim 1, wherein the release-controlling layer is an enteric layer.

3. 3. The medicinal particle according to claim 2, wherein the coating portion further comprises a shielding layer interposed between the enteric layer and the spherical core portion.

4. The medicinal particle according to any one of claims 1 to 3, wherein the coating portion comprises a first shielding layer, a second shielding layer, a first enteric layer, an intermediate layer, a second enteric layer and an outermost layer laminated in that order on the spherical core.

5. The medicinal particle according to any one of claims 1 to 4, wherein the outermost layer does not contain a disintegrant.

6. The medicinal particle according to any one of claims 1 to 5, wherein the medicinal ingredient is esomeprazole or a salt and / or solvate thereof.

7. The medicinal particles according to any one of claims 1 to 6, having a median particle size of 460 to 550 µm.

8. The method for producing medicinal particles according to any one of claims 1 to 7, wherein the medicinal particles are obtained by covering a spherical core with a coating portion.

9. An orally disintegrating tablet comprising the medicinal particles according to any one of claims 1 to 7.

10. The orally disintegrating tablet according to claim 9, further comprising rapidly disintegrating particles.

11. The orally disintegrating tablet according to claim 10, wherein the rapidly disintegrating particles contain a sugar alcohol and carmellose, and the proportion of crystalline cellulose in the particles is less than 1% by mass.

12. The orally disintegrating tablet according to claim 10 or 11, wherein the rapidly disintegrating particles do not contain any medicinal ingredient.

13. A medicinal particle formed of a spherical core containing a medicinal ingredient and a coating part that covers the spherical core and includes a release control layer and an outermost layer containing mannitol, The proportion of mannitol in the outermost layer is adjusted to 95% by mass or more, The proportion of mannitol contained in the outermost layer is adjusted to 4 to 15% by mass in the medicinal particles; and A method for suppressing the occurrence of cracks during tableting to prepare an orally disintegrating tablet containing these medicinal particles by adjusting the particle hardness to 400 gf or more.

Citation Information

Patent Citations

  • Method of trimming changing characteristics of variable resistor

    JP1978066558A

  • Method for molding high precision molded item

    JP1989040313A

  • Granule for tableting, production thereof and tablet

    JP1991240723A

  • Composition for preventing breakage of enteric layer

    JP2018118936A

  • Disintegrating particle composition and orally rapidly disintegrating tablet

    WO2011019045A1